All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Is sustained treatment with KD025 required for cGvHD control?
Bookmark this article
The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Madan H. Jagasia, Vanderbilt University Medical Center, Nashville, US, was based on the question: Is sustained treatment with KD025 required for chronic graft-versus-host disease control?
Madan Jagasia discusses the mechanism of action of KD025 treatment. He also shares his data of the 24 months follow-up of patients treated with this molecule and explains a subset of patients may benefit from longer exposure of treatment. He concludes by explaining there is a pivotal trial that is exploring the effects of prolonged exposure to KD025 in the cGvHD setting and will hopefully provide more answers.
Is sustained treatment with KD025 required for cGvHD control?
More about...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox